Track Your CD4 Count and Viral Load! Use TheBody.com's New Health Tracker!

BROWSE TOPICS IN HIV TREATMENT:

HIV Treatment: Home Page

Just Diagnosed

HIV Medications

First Steps to Treatment

HIV Drug Resistance

Switching or Stopping Treatment

Third Line/Rescue Treatment

Hepatitis C Coinfection

Women & Pregnancy

HIV Treatment for Children

Side Effects & Health Problems

Research & Experimental Drugs

HIV Treatment in the Developing World

Research on Lipodystrophy & Other Metabolic Complications

Overview | Fat Accumulation Research | Lipoatrophy Research

See also: Lipodystrophy Basics

Show Archived (Historical) Articles

Overview

HIV/HCV-Coinfected Patients Appear More Likely Than HIV-Monoinfected Patients to Develop Insulin Resistance After Initiating HAART (February 5, 2008)
From The Body PRO
Body Fat Changes Becoming Less Common as HIVers Use Fat-Friendlier Meds, Study Finds (January 23, 2008)
In HIV Medicine
Hepatitis C Coinfection Doesn't Increase the Risk of Lipoatrophy (May 21, 2007)
A pair of new U.S. studies appears to contradict long-held concerns that HIV/hepatitis C-coinfected people have a higher risk of diabetes and lipoatrophy (fat loss).
From aidsmap.com

Increased Fat Consumption Observed in People With HIV With High Cholesterol (August 22, 2007)
From aidsmap.com
Dietary Intervention When Starting HAART Prevents the Increase in Lipids Independently of Drug Regimen: A Randomized Trial (July 25, 2007)
From International AIDS Society
The Role of Nucleoside Analogs in the Development of Insulin Resistance (July 24, 2007)
NRTIs to date have been thought to contribute to insulin resistance mainly via induction of lipoatrophy. The authors of this paper put forth another potential mechanism based on their findings: that is, zidovudine (AZT, Retrovir)-mediated mitochondrial toxicity in skeletal muscle, adipocytes and hepatocytes. Margaret Hoffman-Terry, M.D., reports.
In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
Testosterone Levels, Fat Free Mass, Increases Differ According to HIV Drugs Taken (June 4, 2007)
From aidsmap.com
Metabolic Complications: A CROI Round-Up (February 28, 2007)
Includes an analysis of research examining lopinavir/ritonavir vs. efavirenz, the use of growth hormone releasing factor to treat fat gain, the link between cardiovascular disease and HIV treatment, the use of ezetimibe (a choleserol-reducing agent) and the latest on bone health in HIV-infected patients.
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Metabolic Syndrome as Common in HIV-Negative as in HIV-Positive Individuals (February 15, 2007)
From aidsmap.com

Metabolic Complications of HIV Therapy (September 2006)
To read PDF, click here
In IAPAC Monthly, from International Association of Physicians in AIDS Care
Initiation of HAART May Increase Free Testosterone Levels and Fat-Free Mass (August 17, 2006)
In XVI International AIDS Conference
Metabolic Complications at the XVI International AIDS Conference: Part 1 -- An Overview of New Data (August 17, 2006)
In XVI International AIDS Conference
Metabolic Complications at the XVI International AIDS Conference: Part 2 -- Lipids (August 17, 2006)
In XVI International AIDS Conference
Research in Anti-Lipo Therapy Headlines AIDS Confab (February 8, 2006)
In The 13th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
PI-Based Therapy Does Not Increase Glucose Intolerance, Gestational Diabetes in Pregnant, HIV-Infected Women (February 6, 2006)
In The 13th Conference on Retroviruses and Opportunistic Infections
HIV JournalView: Metabolic Complications and HAART: Some New Answers and Many More Questions (January 2006)
Part of David Wohl, M.D.'s review of the top 10 HIV research reports of 2005.
In HIV JournalView, from The Body PRO

HIV JournalView: Study Ties Insulin Resistance to NRTIs, Not PIs (September 2005)
d4T and 3TC are associated with insulin resistance and high insulin levels; indinavir is associated only with elevated insulin levels; and no link to insulin abnormalities is found for AZT or ddI.
From The Body PRO
Moderate Weight Loss Increasingly Common for HIVers on HAART (September 1, 2005)
Wasting syndrome may be on the decline, but moderate weight loss -- of 5% or more -- has increased steadily since 1995, and appears unrelated to lipodystrophy.
From aidsmap.com

Antioxidants Have Little Benefit in People With Lipoatrophy (August 29, 2003)
A combination of vitamin E, vitamin C and N-acetylcysteine has positive and negative health results.
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention

Extensive Coverage of the 2nd International Workshop on Adverse Drug Reactions and Lipodystrophy (ADRL 2000) (September 13-15, 2000)
By The Body's expert, Dr. Pablo Tebas.
In The 2nd International Workshop on Adverse Drug Reactions and Lipodystrophy, from The Body PRO

The Body is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.